复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

未开盘 12-19 16:08:47

23.850

+0.000

0.00%

最高23.900	最低23.700	成交量58.89万
今开23.800	昨收23.850	日振幅0.84%
总市值129.62亿	流通市值38.88亿	总股本5.43亿
成交额1,404万	换手率0.36%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":23.85,"timestamp":1734595727016,"preClose":23.85,"halted":0,"volume":588900,"delay":0,"floatShares":163000000,"shares":543494853,"eps":1.0780895,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"12-19 16:08:47","open":23.8,"high":23.9,"low":23.7,"amount":14039930,"amplitude":0.008386,"askPrice":23.85,"askSize":19300,"bidPrice":23.8,"bidSize":28200,"shortable":3,"etf":0,"ttmEps":1.3623163998693644,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1569340800000,"adjPreClose":23.85,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.6969206025167872,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2492106308","title":"复宏汉霖(02696.HK)与Palleon订立合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492106308","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492106308?lang=zh_cn&edition=full","pubTime":"2024-12-20 00:30","pubTimestamp":1734625800,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布，与Palleon订立合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。本次合作不涉及首付款，公司将向Palleon支付里程碑款项合计不超过9,530万美元，以及以年度净销售额8%-12%计的特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405369/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492120570","title":"复星医药子公司复宏汉霖与Palleon签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120570","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492120570?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:57","pubTimestamp":1734613061,"startTime":"0","endTime":"0","summary":"12月19日晚间，复星医药发布公告称，公司控股子公司复宏汉霖与Palleon签订《合作与许可协议》，根据约定，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域内的全球合作开发及于各自许可区域内的商业化开展合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219210704a1fb320f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219210704a1fb320f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","BK1191","02696","02196","BK1593"],"gpt_icon":0},{"id":"2492124769","title":"聚焦自免疾病，复宏汉霖与Palleon合作推进糖编辑疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2492124769","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492124769?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:20","pubTimestamp":1734610855,"startTime":"0","endTime":"0","summary":"Palleon是一家领先的专注开发糖免疫药物用于治疗癌症和炎症性疾病的公司。复宏汉霖将负责E-602联合汉利康用于治疗LN在中国的临床开发并承担相应资金。此次合作进一步扩展了复宏汉霖与Palleon的合作。复宏汉霖执行董事、首席执行官朱俊博士我们很高兴能与糖免疫这一新兴领域的领导者——Palleon进一步扩大合作。汉利康是目前国内唯一获批用于自身免疫疾病治疗的利妥昔单抗产品。据悉，E-602是Palleon的EAGLE糖编辑平台开发的同类首创的人唾液酸酶融合蛋白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121920205995ea773f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121920205995ea773f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492121122","title":"复宏汉霖与Palleon签署合作协议，开发新型免疫治疗产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2492121122","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492121122?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:00","pubTimestamp":1734609600,"startTime":"0","endTime":"0","summary":"财中社12月19日电复宏汉霖 发布公告，宣布与Palleon Pharmaceuticals Inc.签署了一项合作及许可协议。根据该协议，双方将就E-602及联合疗法在全球范围内进行合作开发和商业化。公司将获得Palleon在中国的独家许可，而Palleon则在全球其他地区拥有该产品的许可权。此次合作不涉及首付款，但公司需向Palleon支付最高5280万美元的开发里程碑款项，以及最高4250万美元的销售里程碑款项。该合作有望推动公司在肿瘤及自身免疫疾病治疗领域的研发进展，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219200458ab845b07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219200458ab845b07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492912523","title":"复宏汉霖就E-602及联合疗法与PALLEON订立合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492912523","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492912523?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:47","pubTimestamp":1734605227,"startTime":"0","endTime":"0","summary":"合作及许可协议订立后，公司拟开展有关许可产品联合汉利康用于治疗狼疮肾炎适应症的临床研究。本次合作有望借助许可产品增强汉利康对自身免疫疾病的治疗效果。公司已与Palleon就两款肿瘤相关靶点唾液酸酶融合蛋白建立良好合作关系。本次合作有望基于双方现有技术，共同推进许可产品及联合疗法的研发，进一步丰富公司产品管线，进而增强公司在肿瘤及自身免疫类疾病治疗领域的综合市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219185050ab84385b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219185050ab84385b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492406481","title":"复宏汉霖(02696)：就E-602及联合疗法与PALLEON订立的合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492406481","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492406481?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:33","pubTimestamp":1734604422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，公司已于2024年12月19日与Palleon Pharmaceuticals Inc.订立一份合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。合作及许可协议订立后，公司拟开展有关许可产品联合汉利康用于治疗狼疮肾炎适应症的临床研究。本次合作有望借助许可产品增强汉利康对自身免疫疾病的治疗效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492147708","title":"复星医药：控股子公司签署药品合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147708","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492147708?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:27","pubTimestamp":1734604032,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","BK1191","BK1593","BK1583","02196","BK0239","03347","BK0188","600196","BK0012","BK1576","BK0196","BK0175","BK0187","BK0028","BK0060","BK0183","BK0096","BK1515","02696","BK1141"],"gpt_icon":0},{"id":"2492147795","title":"复星医药最新公告：控股子公司复宏汉霖与Palleon签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492147795?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:21","pubTimestamp":1734603679,"startTime":"0","endTime":"0","summary":"复星医药公告，控股子公司复宏汉霖与Palleon签订《合作与许可协议》，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域（即用于人类疾病治疗）内的全球合作开发及于各自许可区域内的商业化开展合作。E-602是一种唾液酸酶融合蛋白，拟用于肿瘤以及自身免疫类疾病的治疗。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900031654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0196","BK0239","BK1161","BK1191","02696","BK1515","600196","02196","BK1593","BK0183","BK0096","BK0187","BK0012","BK0175","BK0028"],"gpt_icon":0},{"id":"2492555147","title":"复星医药：子公司复宏汉霖与Palleon签订合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492555147","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492555147?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:16","pubTimestamp":1734603364,"startTime":"0","endTime":"0","summary":"复星医药12月19日公告，12月19日，公司控股子公司复宏汉霖与Palleon签订《合作与许可协议》，根据约定，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域（即用于人类疾病治疗）内的全球合作开发及于各自许可区域内的商业化开展合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219181604a1fae3a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219181604a1fae3a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","02196","02696","BK1161","BK1515"],"gpt_icon":0},{"id":"2492395662","title":"股价跳涨逾6%！复宏汉霖私有化尘埃落定？","url":"https://stock-news.laohu8.com/highlight/detail?id=2492395662","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492395662?lang=zh_cn&edition=full","pubTime":"2024-12-17 20:07","pubTimestamp":1734437271,"startTime":"0","endTime":"0","summary":"今年下半年以来，多家港股公司遭遇私有化退市，涉及赛生药业、欧舒丹等。而在近期，“复星系”旗下的复星旅游文化（01992.HK）、复宏汉霖（02696.HK）也接连传出私有化相关的消息。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202412_1/83bd7d75-803b-4ae0-b603-008cce1520a3.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202412_1/83bd7d75-803b-4ae0-b603-008cce1520a3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67616997bde0b36e3c053c6a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492938505","title":"港股收盘(12.17) | 恒指收跌0.48% 部分中特估逆势上扬 中兴通讯(00763)一度涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492938505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492938505?lang=zh_cn&edition=full","pubTime":"2024-12-17 16:37","pubTimestamp":1734424655,"startTime":"0","endTime":"0","summary":"截止收盘，恒生指数跌0.48%或95.01点，报19700.48点，全日成交额为1319.89亿港元；恒生国企指数跌0.38%，报7105.44点；恒生科技指数跌0.58%，报4389.08点。截至收盘，涨2.29%，报66.95港元，成交额7.33亿港元，贡献恒指1.81点。美联储即将在12月17日至18日召开今年最后一次的议息会议。截至收盘，涨4.64%，报20.3港元。中兴通讯早盘一度涨超9%，公司A股一度涨停。截至收盘，跌14.44%，报0.77港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f4619f9eb534dbb52cb7bf795ec019ab","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0103","02833","BK1198","BK1526","BK0012","LU0140636845.USD","BK1529","00317","BK0026","HSTECH","BK1149","BK0167","LU0326950275.SGD","HHImain","LU2328871848.SGD","BK0214","BK0171","BK1114","BK1161","HSI","LU1580142542.USD","BK0028","000063","00763","BK0125","BK0196","YANG","BK0018","513600","BK0058","MCHmain","BK0188","LU1781817850.SGD","BK0090","06110","BK1544","BK1607","HSCEI","BK1215","BK0183","BK1506","LU1328615791.USD","BK0000","01161","BK0030","LU1969619763.USD","01787","BK0123","02696"],"gpt_icon":1},{"id":"2492987031","title":"复宏汉霖上榜12月17日主力资金加仓幅度前10个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2492987031","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492987031?lang=zh_cn&edition=full","pubTime":"2024-12-17 16:17","pubTimestamp":1734423430,"startTime":"0","endTime":"0","summary":"12月17日, 复宏汉霖股价涨6.07%，报收23.60元，成交金额5607万元，换手率1.46%，振幅2.02%，量比22.37。复宏汉霖今日主力资金净流入1270万元，上一交易日主力净流入30万元，今日环比增加4133.33%。该股近5个交易日上涨5.83%，主力资金累计净流入1296万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1996万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161814a1f543eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217161814a1f543eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492728656","title":"复宏汉霖高开逾5% 复星医药称吸收合并复宏汉霖的前提条件已达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2492728656","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492728656?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:40","pubTimestamp":1734399600,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　复宏汉霖（02696）早盘高开，股价上涨5.17%，现报23.40港元，成交额587.92万港元。\n　　复星医药公布，已达成以吸收合并复宏汉霖的前提条件，所有相关政府批准已于2024年12月16日完成。综合文件预计于2024年12月23日或之前寄发给股东。合并协议的生效仍需满足特定条件，股东及潜在投资者应谨慎行事。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-17/doc-incztptx1863684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","600196","BK0012","BK0096","BK0060","BK0187","BK1515","BK1593","BK1191","BK0175","BK0028","BK0188","02196","BK0239","BK1161","02696","BK0196"],"gpt_icon":0},{"id":"1134851177","title":"异动解读 | 复宏汉霖股价大涨5.39%,大股东复星医药私有化前提条件已达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1134851177","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134851177?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:32","pubTimestamp":1734399151,"startTime":"0","endTime":"0","summary":"复宏汉霖股价今日盘中大涨5.39%,引发市场广泛关注。这一涨幅与公司最新发布的消息有关:公司大股东复星医药以吸收合并方式将复宏汉霖私有化的前提条件已全部达成。复星医药预计将很快向复宏汉霖公众股东寄发综合文件,就是次私有化交易征求股东审议。市场人士认为,此次涉及私有化的利好消息释放出正面信号,体现出复星医药对复宏汉霖发展的信心与决心,因而推动了复宏汉霖股价今日上扬。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 复宏汉霖股价大涨5.39%,大股东复星医药私有化前提条件已达成","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02696"],"gpt_icon":0},{"id":"2492175671","title":"复宏汉霖(02696)上涨5.84%，报23.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492175671","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492175671?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399011,"startTime":"0","endTime":"0","summary":"12月17日，复宏汉霖(02696)盘中上涨5.84%，截至09:30，报23.55元/股，成交459.55万元。上海复宏汉霖生物技术股份有限公司是一家专注于生物制药的公司，主要为全球患者提供高品质生物药，产品涵盖肿瘤、自身免疫疾病、眼科疾病等领域。公司已在中国上市5款产品，在国际上市2款产品，19项适应症获批，7个上市申请分别获中国药监局、美国FDA和欧盟EMA受理，同时在全球范围内开展30多项临床试验。截至2024年中报，复宏汉霖营业总收入27.46亿元、净利润3.86亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/17093046454744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492674389","title":"复宏汉霖盘中异动 大幅上涨6.07%报23.600港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492674389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492674389?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399004,"startTime":"0","endTime":"0","summary":"2024年12月17日早盘09时30分，复宏汉霖股票出现异动，股价急速上涨6.07%。截至发稿，该股报23.600港元/股，成交量19.66万股，换手率0.12%，振幅1.35%。资金方面，该股资金流入231.38万港元，流出4.239万港元。复宏汉霖股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，和铂医药-B、复宏汉霖、华康生物医学涨幅较大，振幅较大的相关个股有和铂医药-B、科济药业-B、晶泰控股-P，振幅分别为3.51%、3.01%、1.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093004a1f46915&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093004a1f46915&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492671915","title":"港股异动 | 复宏汉霖(02696)高开逾4% 复星医药称吸收合并复宏汉霖的前提条件已达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2492671915","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492671915?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:24","pubTimestamp":1734398656,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖高开逾4%，截至发稿，涨4.72%，报23.3港元，成交额219.72万港元。消息面上，复星医药公布，已达成以吸收合并复宏汉霖的前提条件，所有相关政府批准已于2024年12月16日完成。合并协议的生效仍需满足特定条件，股东及潜在投资者应谨慎行事。据悉，复星医药今年6月份公布，建议以吸收合并方式将复宏汉霖私有化，每股H股现金注销价24.6港元。条件达成后 ，复宏汉霖将向联交所申请自愿撤销H股的上市地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0028","600196","BK0196","BK1515","BK0187","BK0060","BK1161","BK0239","BK0175","BK1191","BK0183","02696","02196","BK0096","BK0188","BK1593"],"gpt_icon":0},{"id":"2492679443","title":"港股开盘，恒指开跌0.59%，科指开跌0.61%。生物医药股部分高开，复宏汉霖(02696.HK)开涨4.72%，君实生物(01877.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492679443","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492679443?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:22","pubTimestamp":1734398525,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["01877","02833","399441","BK1583","02696","BK1515","HSTECH","MCHmain","688180","07226","BK0239","HHImain","HSImain","YANG","161726","BK1161","HSI","MHImain","513600","HSCEI"],"gpt_icon":0},{"id":"2492730476","title":"【湾区早参】香港政府拟明年首季提选举安排修订草案；深圳首个离境退税陆路口岸退税点启用","url":"https://stock-news.laohu8.com/highlight/detail?id=2492730476","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492730476?lang=zh_cn&edition=full","pubTime":"2024-12-17 08:34","pubTimestamp":1734395646,"startTime":"0","endTime":"0","summary":"自12月16日起，深圳文锦渡口岸正式实施境外旅客购物离境退税政策，境外旅客在该口岸离境时，其在退税商店购买的退税物品，经海关验核确认后，由相关部门联合评定的退税代理机构对其退还增值税。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949737","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00670","BK1593","BK1161","BK1561","BK1191","BK1514","BK1555","BK1148","01055","06055","BK1240","02196","BK1123","06185","06110","BK1574","BK1512","BK1580","BK1515","02696","02777","BK1181","BK1114","09900"],"gpt_icon":0},{"id":"2492612711","title":"复宏汉霖(02696.HK)大股东复私有化建议前提条件均已达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2492612711","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492612711?lang=zh_cn&edition=full","pubTime":"2024-12-17 01:14","pubTimestamp":1734369240,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布，大股东复星医药(02196.HK) 以吸收合并方式将公司私有化之前提条件均已达成。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-16 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180119144849220_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180119144849220_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1404458/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02696"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0695},{"period":"1month","weight":0.1749},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.2659},{"period":"1year","weight":1.0246},{"period":"ytd","weight":0.7158}],"compareEarnings":[{"period":"1week","weight":-0.0316},{"period":"1month","weight":0.0045},{"period":"3month","weight":0.0818},{"period":"6month","weight":0.0956},{"period":"1year","weight":0.1889},{"period":"ytd","weight":0.1587}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01（汉利康）、赫赛汀（曲妥珠单抗）生物类似药HLX02、修美乐（阿达木单抗）生物类似药HLX03和安维汀（贝伐珠单抗）生物类似药HLX04以及候选生物创新药，包括HLX06（一种新型VEGFR2抑制剂）、HLX07（一种EGFR抑制剂）、HLX10（一种新型PD-1抑制剂）、HLX20（一种新型PD-L1抑制剂）及HLX22（一种新型HER2抑制剂）等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.004462},{"month":2,"riseRate":0.6,"avgChangeRate":0.003175},{"month":3,"riseRate":0.4,"avgChangeRate":-0.070667},{"month":4,"riseRate":0.8,"avgChangeRate":0.127521},{"month":5,"riseRate":0.4,"avgChangeRate":-0.068918},{"month":6,"riseRate":0.6,"avgChangeRate":0.1049},{"month":7,"riseRate":0.4,"avgChangeRate":0.0182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.051626},{"month":9,"riseRate":0,"avgChangeRate":-0.146246},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.017718},{"month":11,"riseRate":0.666667,"avgChangeRate":0.070363},{"month":12,"riseRate":0.833333,"avgChangeRate":0.002342}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}